An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate.
about
Phosphate binders for preventing and treating bone disease in chronic kidney disease patientsManaging hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulnessNanoporous sorbent material as an oral phosphate binder and for aqueous phosphate, chromate, and arsenate removalFerric citrate controls phosphorus and delivers iron in patients on dialysis.Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity.Ferric citrate.Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Phosphate binders: new products and challenges.Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model.The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.Next-generation phosphate binders: focus on iron-based binders.Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis.Novel iron-containing phosphate binders for treatment of hyperphosphatemia.Emerging drugs for the treatment of kidney disease-induced anemia.Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification.Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease.The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats
P2860
Q24234036-38395F32-A18D-408F-BDEE-F9DA6BE2773AQ26786000-350203F5-288B-4B57-B6AF-E146427E9679Q28385247-4C377081-457E-4633-91AE-C3CF706B2426Q30361082-89251689-6982-440C-9BEB-1F347A3000FAQ30854189-D20341B9-871F-4DBF-9006-798F988F1AA6Q34411365-2E397861-D991-422E-9589-29FB8DCA2F90Q35106352-17DA2C6B-15E5-4BE6-A937-68FDAD3B3DECQ36225208-8EF440DE-06CD-402F-B190-E0604A20F1FCQ36522027-A56260F7-B44B-4E01-B9DD-69346D2D3EC3Q36825820-346B4A19-7B0D-4BDB-A8AF-BDAE237CA8E8Q36904701-8052C7BC-3923-43A1-B1EB-449844326A71Q38213502-9E5D8B5E-88F1-40FA-9A72-634FB727B381Q38263310-E18E67B9-8653-4A7B-AB5C-2AF788DD3996Q38570622-A44747D7-6991-41CB-80C2-B790F6638FE3Q38930912-428B0E45-0290-46A0-8D90-DBC55465ED61Q39440902-C1C2DE84-4E8C-455D-B47A-617E2A2F4363Q44568211-3B023B65-E508-4FE0-877B-F3C28D3DFC8EQ45902059-3A1A0E7B-9B47-48E0-851D-81C27DD3F621Q46915404-E81BB25D-864B-481B-8DDB-D21A0761CC94Q47101477-18B5957F-4B80-47F3-B5C1-6D35927AC16BQ47114967-780D3A3A-E701-4438-B539-5C7325F66C4FQ57216834-EBE84812-4A45-4B3A-A4F0-4C006386E9C8
P2860
An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
An open-label, crossover study ...... ysis patients: ferric citrate.
@en
An open-label, crossover study ...... ysis patients: ferric citrate.
@nl
type
label
An open-label, crossover study ...... ysis patients: ferric citrate.
@en
An open-label, crossover study ...... ysis patients: ferric citrate.
@nl
prefLabel
An open-label, crossover study ...... ysis patients: ferric citrate.
@en
An open-label, crossover study ...... ysis patients: ferric citrate.
@nl
P2093
P356
P1476
An open-label, crossover study ...... ysis patients: ferric citrate.
@en
P2093
Chen H Hsu
Chun-Chen Hou
Chwei-Shiun Yang
Eric W Young
Tsai-Hung Wu
Wu-Chang Yang
P304
P356
10.1093/NDT/17.2.265
P407
P577
2002-02-01T00:00:00Z